ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Shanghai Pharmaceuticals has offered to acquire a majority stake, later to be followed by 100% ownership, in Changzhou Kony Pharma, a manufacturer of active pharmaceutical ingredients (APIs). Shanghai Pharmaceuticals’ offer values Kony at $48 million. Established in 1986 in Changzhou, Jiangsu province, Kony specializes in nucleoside antiviral APIs and losartan, a blood pressure drug that lost patent protection in 2009. Shanghai Pharmaceuticals says the Changzhou site will complement other API facilities it is building in Shanghai’s Xinghuo development zone.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X